24/7 BioPharma: Navigating Complexity- Industry Leaders on Bioprocessing, Manufacturing and Partnership Models

Ahead of the BIO International Convention, a panel of industry leaders from bioprocess, cell‑line development, CDMOs and advanced‑therapy service providers discussed with 24/7 Biopharma how rising molecular complexity, cost pressures and evolving market dynamics are reshaping development and manufacturing. From next‑generation modalities and data‑driven process design to new partnership and operating models, this roundtable explored practical strategies for accelerating translational decisions, scaling manufacture and de‑risking the path from discovery to commercial supply.

Abzena’s contributing author: John Gill, VP & Scientific Leader- Cell Line Development

Q. What are the biggest trends currently shaping your organization and the wider life sciences sector?

JG. One of the biggest trends shaping both Abzena and the wider life sciences sector is the rapid growth of next-generation biologics, including bispecifics, fusion proteins and increasingly sophisticated bioconjugates such as antibody-oligonucleotide conjugates. These modalities are creating exciting new therapeutic opportunities, but they also bring greater scientific, technical, and manufacturing complexity.

As a result, success now depends not only on a deep understanding of the science required to design and de-risk these molecules, but also on the ability to scale and manufacture them efficiently with future commercial requirements in mind. At the center of this is the need for robust, adaptable production platforms, including cell line development and other enabling technologies that can accommodate the increasing diversity and complexity of emerging therapeutic formats.

Q. How are changing market conditions influencing your strategy & priorities for the coming year?

JG. Changing market conditions are reinforcing our belief that Abzena is in the right place at the right time. The industry is increasingly focused on advanced biologics and bioconjugates, and our scientific and technical capabilities are well aligned to support companies developing these complex next-generation medicines.

For the coming year, this means continuing to strengthen our ability to improve manufacturing efficiency, reduce development risk and support programs as they progress towards later-stage clinical development, Phase III, and ultimately commercial supply. Our priority is to ensure that promising science can be translated into manufacturable, scalable and commercially viable products.

Q. What innovations or developments are you most excited about within your areas of expertise?

JG. I am particularly excited by innovations that make complex biologic and bioconjugate development more versatile, efficient and scalable. This includes the development of better, more adaptable cell line development platforms that can support a broader range of molecular formats and help accelerate early development decisions.

I am also excited by the move towards more contiguous downstream processes for antibody purification and conjugation. By reducing process breaks, shortening timelines and improving control, these approaches have the potential to reduce time, cost and risk, while improving the path from development into scalable manufacture.

Q. What do you see as the biggest challenges facing biopharma companies today, and how is Abzena helping to address them?

JG. One of the biggest challenges facing biopharma companies today is convincing investors and other stakeholders that next-generation drugs are not only scientifically exciting, but also investable and manufacturable. Companies need to connect compelling early proof-of-concept data with a credible path to making the drug at scale. Abzena helps address this by combining expertise in diverse molecular design with practical experience in drug development and manufacturing.

A second major challenge is navigating the regulatory pathway for novel molecules with little or no IND precedent. This places a premium on thoughtful data generation and on linking structure, function, PK/PD and safety in a clear development rationale. Abzena is well positioned to support this through its breadth and depth of analytical, bioassay, developability, lead candidate selection and manufacturing capabilities.

Q. What key message or insight are you hoping to share with industry stakeholders at BIO this year?

The key message I hope to share with industry stakeholders at BIO is that this is an exciting moment for drug development. Scientific innovation is opening up the possibility of treating diseases that have historically been very difficult to address, but success will depend on the ability to connect discovery, development, manufacturing and regulatory strategy from the outset.

In summary, the future of advanced therapeutics will be shaped by organizations that can combine scientific insight with practical execution. Abzena’s role is to help customers de-risk complex molecules, generate the right data, and build a scalable path from concept to clinic and ultimately to commercial supply.

Click Here to Access the Article